Industry Slams Japan's Regulatory Reforms

June 2006 | Market Trend Analysis

Stakeholders in Japan's drug industry have criticised the government's handling of its five-year industry plan. The strategy was first outlined in 2002, and a draft version of the new five-year plan is expected later this year. Although the government's overall vision has been praised by a wide cross-section of the industry, a lack of clear targets has led to uneven implementation of the plan. Red tape has been widely blamed for the fact that many innovative medicines are introduced later in Japan than in other developed markets.

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.